
ENDRA Life Sciences
3600 Green Court, Suite 350, Ann Arbor, MI, 48105-1570, United States
Overview
ENDRA Life Sciences develops Thermo Acoustic Enhanced UltraSound (TAEUS), a non-invasive imaging technology designed to quantify fat content in tissues and track liver conditions such as steatosis. The platform seeks to offer clinicians a cost-effective alternative to MRI and biopsy for assessing liver fat. To bolster its balance sheet and diversify cash management, ENDRA has launched a digital-asset treasury program, beginning with the purchase of 78,863.1 HYPE tokens valued at roughly $3 million as of 21 October 2025. The company’s digital-asset strategy, advised by Arca Investment Management, will use techniques such as options overlays, staking, and DeFi participation to generate yield and increase tokens-per-share. Management anticipates that returns from these activities could be reinvested into operations and M&A opportunities related to crypto. Recent financing provides near-term working capital while future warrant exercises could add an incremental $9.5 million. No operating metrics such as revenue or user counts were disclosed in the articles.
- Total raised
- $8M
- Funding rounds
- 2
- Latest round
- Initial Coin Offering
- Latest activity
- Oct 2025
Industries
- Biotechnology
- Health Care
- Medical Device
Recent funding
Initial Coin Offering
Oct 2025
$3M